MONTREAL – Global drug giant GlaxoSmithKline (NYSE: GSK ) will spend $50 million to expand its vaccine research plant in Laval, Que., just north of Montreal, expanding its workforce by 60 jobs.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best ...

GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech. The licensing is part of the ...

GSK has previously said it was committed to supplying up to 18 million vaccine doses between 2023 and the end of this year. The company plans to supply 15 million doses annually from 2026-2028 ...

GSK expects to provide between 28- and 33 million doses of flu vaccine to the U.S. market this fall; about 23 million of that will come from the Quebec plant, Smolenaars Hunter said.

GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance© Stocktwits GSK's Sentiment Meter and Message Volume as of 8:30 a.m. ET on July 14, 2025 ...

In 2021, GSK had inked a product transfer agreement for the world's first malaria vaccine, RTS,S, with Bharat Biotech. Follow more information on Air India plane crash in Ahmedabad here.

GSK has previously said it was committed to supplying up to 18 million vaccine doses between 2023 and the end of this year. The company plans to supply 15 million doses annually from 2026-2028 ...

LONDON (Reuters) -Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to below $5 per dose by 2028, more than halving its current cost, they said on Wednesday. The vaccine, ...